Free tool
FAERS Monitor: Symfi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022142 or its brand name (Symfi, Efavirenz, Lamivudine, Tenofovir Disoproxil Fumarate). Reports on generic versions are filed under their own applications.
Reports
30
Serious
21
70% of reports
Hospitalization
3
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anhedonia8
- anxiety8
- emotional distress8
- pain8
- bone density decreased6
- foetal exposure during pregnancy4
- headache4
- osteoporosis4
- renal failure4
- back pain3
- bone demineralisation3
- chronic kidney disease3
- gait disturbance3
- acute kidney injury2
- dizziness2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 8 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,129 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bone demineralisationSignal | 3 | 1993.8 | 680.3 | 4,137 |
| anhedoniaSignal | 8 | 213.5 | 117.9 | 1,488 |
| bone density decreasedSignal | 6 | 134.3 | 65.6 | 667 |
| osteoporosisSignal | 4 | 68.2 | 27.4 | 202 |
| emotional distressSignal | 8 | 46.3 | 25.6 | 313 |
| foetal exposure during pregnancySignal | 4 | 34.5 | 13.9 | 99 |
| chronic kidney diseaseSignal | 3 | 27.7 | 9.5 | 53 |
| renal failureSignal | 4 | 21.1 | 8.5 | 58 |
| anxietySignal | 8 | 19.7 | 10.9 | 126 |
| gait disturbanceSignal | 3 | 11.0 | 3.8 | 18 |
| acute kidney injury | 2 | 9.2 | 2.4 | 8 |
| painSignal | 8 | 9.1 | 5.0 | 52 |
| back painSignal | 3 | 9.1 | 3.1 | 14 |
| headacheSignal | 4 | 4.5 | 1.8 | 8 |
| dizziness | 2 | 2.8 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.